A new federally funded analysis of more than 107 million adults with employer‑sponsored insurance found that states with medical cannabis dispensaries and recreational cannabis laws saw meaningful reductions in non‑fatal opioid overdoses. The most striking result came from medical dispensary access, which was associated with a 15.47% decline in overdose diagnoses. Recreational legalization was associated with a 11.92% reduction.
The study, published in Preventive Medicine Reports, adds a large new data set to the ongoing discussion about whether cannabis availability influences opioid‑related harms.
The authors introduced their research by noting the ongoing uncertainty surrounding the issue.
“Although many states have legalized medical and recreational cannabis, its association with non-fatal opioid poisonings remains unclear,” they wrote. “This study examines the association between state cannabis legalization policies and non-fatal opioid poisoning diagnoses among enrollees in employer-sponsored health insurance.”
Younger Adults Saw The Largest Declines
The reductions were not evenly distributed across age groups. According to the authors, “The reductions tied to medical dispensaries were significant for both men and women, and especially notable among younger adults ages 18–34, who saw a 23.27 percent reduction.”
The study notes that this population has been underrepresented in earlier research, which often focuses on Medicaid enrollees or the general population. By isolating commercially insured adults, the authors were able to identify trends in a group that has historically been less studied in cannabis‑opioid research.
Evidence Points Toward A Substitution Effect
The authors suggest that increased access to regulated cannabis via a medical cannabis dispensary (MCD) and recreational cannabis laws (RCL) may be influencing how some adults manage pain or other conditions.
“These findings suggest that expanded access to cannabis through MCD and RCL is associated with lower [non-fatal opioid overdoses among] adults with employer-sponsored insurance,” they wrote. “Greater cannabis access through MCDs and RCL may reduce [overdoses] in heavily impacted populations, indicating possible substitution of cannabis for opioids.”
The paper stops short of claiming cannabis alone is responsible for the reductions, but the consistency of the associations across multiple models strengthens the case for a substitution effect.
Legalization As A Complement, Not A Replacement
The researchers emphasized that cannabis access should not be viewed as a standalone solution to the opioid crisis.
“Findings support continuing evidence-based opioid use disorder treatments, while policymakers treat legalization as complementary and prioritize harm reduction and treatment expansion,” they concluded.
Their recommendation aligns with a growing body of public health literature that views cannabis legalization as one tool among many that may help reduce opioid‑related harms when paired with treatment access, education, and broader harm‑reduction strategies.
Findings Consistent with Previous Studies
The new findings also align with previous research, according to a report from Marijuana Moment. Last year, a federally funded study published by the American Medical Association reported that cannabis may function as an effective substitute for opioids in chronic pain treatment. The authors of that paper found consistent evidence that patients with access to legal cannabis were less likely to rely on prescription opioids for long‑term pain management.
Other AMA research has reached similar conclusions. One analysis found that legalizing cannabis for medical or recreational purposes is “significantly associated with reduced opioid use among patients diagnosed with cancer.”
A separate paper published in October added to the trend, reporting that medical cannabis legalization is “associated with significant reductions in opioid prescribing.” That study focused on prescribing behavior rather than overdose outcomes, but the direction of the association was consistent with what the new Preventive Medicine Reports analysis found.
Catch up on the latest cannabis news and sign up for NuggMD's Weekly Sesh newsletter for the latest consumer tips, industry updates, and product recommendations.
The information in this article and any included images or charts are for educational purposes only. This information is neither a substitute for, nor does it replace, professional legal advice or medical advice, diagnosis, or treatment. If you have any concerns or questions about laws, regulations, or your health, you should always consult with an attorney, physician or other licensed professional.
